| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 69448-0022-63 | 69448-0022 | Denosumab-desu | JUBEREQ | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 13, 2026 | In Use | |
| 72606-0038-01 | 72606-0038 | Denosumab-bmwo | Osenvelt | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
| 00143-9166-01 | 00143-9166 | Denosumab-qbde | XTRENBO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 8, 2026 | In Use | |
| 70121-2701-01 | 70121-2701 | Denosumab-mobz | Oziltus | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Dec 23, 2025 | In Use | |
| 61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 83257-0030-11 | 83257-0030 | Denosumab-kyqq | AUKELSO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 5, 2026 | In Use | |
| 55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
| 69448-0021-63 | 69448-0021 | Denosumab-desu | OSVYRTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 6, 2026 | In Use | |
| 55513-0710-21 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Mar 5, 2024 | In Use | |
| 78206-0193-01 | 78206-0193 | Denosumab | BILDYOS | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 11, 2025 | In Use | |
| 72606-0037-01 | 72606-0037 | Denosumab-bmwo | Stoboclo | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
| 61314-0240-63 | 61314-0240 | Denosumab | JUBBONTI | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 50419-0208-01 | 50419-0208 | Radium Ra 223 dichloride | Xofigo | 30.0 uCi/mL | Chemotherapy | Radiopharmaceutical | Radium 223 | Intravenous | May 20, 2013 | In Use | |
| 71288-0119-20 | 71288-0119 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 2, 2021 | In Use | |
| 60505-6115-02 | 60505-6115 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Mar 20, 2018 | Jan 31, 2021 | No Longer Used |
| 00781-3491-94 | 00781-3491 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Nov 1, 2024 | In Use | |
| 00069-0169-01 | 00069-0169 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 18, 2012 | Nov 30, 2014 | No Longer Used |
| 62856-0600-01 | 62856-0600 | Decitabine | Dacogen | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 3, 1996 | Dec 31, 2018 | No Longer Used |
| 62756-0219-60 | 62756-0219 | gemcitabine | INFUGEM | 10.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct 1, 2018 | Jul 31, 2023 | No Longer Used |
| 72606-0555-01 | 72606-0555 | Capecitabine | Capecitabine 500mg | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 6, 2019 | In Use | |
| 67457-0463-02 | 67457-0463 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 2.0 g/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 24, 2014 | Jun 30, 2021 | No Longer Used |
| 72485-0222-10 | 72485-0222 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 1.0 g/26.3mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 15, 2020 | In Use | |
| 62756-0238-88 | 62756-0238 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sep 1, 2019 | In Use | |
| 00409-0187-01 | 00409-0187 | GEMCITABINE | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov 15, 2010 | In Use | |
| 62756-0438-60 | 62756-0438 | gemcitabine | INFUGEM | 10.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct 1, 2018 | No Longer Used |
Found 12611 results — Export these results
Home